公开(公告)号：US5763164A

公开(公告)日：1998-06-09

申请号：US191338

申请日：1994-02-03

Applicant: Emanuel Calenoff

Inventor： Emanuel Calenoff

IPC: G01N33/574 ,  A61K38/00 ,  A61K39/00 ,  A61P37/00 ,  A61P43/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/70 ,  C07K14/82 ,  C12N15/09 ,  C12P21/00 ,  C12P21/02 ,  C12Q1/68 ,  C07H21/02 ,  G01N33/53 ,  C07K15/28

CPC classification number: C07K14/82 ,  Y10S436/818

Abstract: The present invention relates to tumor specific antigens and functional proteins of a tumor cell preparable by identifying protein presents in the tumor cell that are selectively immunogenic for tumor patients. The present invention still further provides a process of making a peptide library of tumor specific humoral antigens, a process of increasing the immunogenic specificity of a tumor-associated antigen, an assay kit for detecting the presence of an antibody immunoreactive with a tumor-specific antigen, and a process of making T cells sensitized to a tumor-specific antigen.

Abstract translation: 本发明涉及肿瘤细胞的肿瘤特异性抗原和功能性蛋白，该肿瘤细胞通过鉴定在肿瘤细胞中存在对肿瘤患者有选择性免疫原性的蛋白质而可制备。 本发明还提供了制备肿瘤特异性体液抗原肽文库的方法，增加肿瘤相关抗原的免疫原性特异性的方法，用于检测与肿瘤特异性抗原免疫反应性的抗体的存在的测定试剂盒 ，以及使肿瘤特异性抗原致敏的过程。

公开(公告)号：US20050272097A1

公开(公告)日：2005-12-08

申请号：US11062186

申请日：2005-02-18

Applicant: Emanuel Calenoff

Inventor： Emanuel Calenoff

IPC: A61K39/00 ,  C07K14/47 ,  G01N33/53 ,  G01N33/564 ,  G01N33/567

CPC classification number: G01N33/564 ,  A61K39/0008 ,  G01N2800/285

Abstract: Diseases caused by or affected by specific antibodies and/or T lymphocytes that complex with self-molecules in a subject are detected by identifying antigen specific antibodies and/or effector T lymphocytes against the antigen, in a biological fluid of an affected subject. This identification opens up treatment possibilities, for example, by desensitization.

Abstract translation: 通过在受影响的受试者的生物液体中鉴定针对抗原的抗原特异性抗体和/或效应T淋巴细胞来检测由受试者中与自身分子复合的特异性抗体和/或T淋巴细胞引起或受其影响的疾病。 这种识别打开了治疗的可能性，例如通过脱敏。

公开(公告)号：US4716120A

公开(公告)日：1987-12-29

申请号：US801649

申请日：1985-11-25

Applicant: Yuh-Geng Tsay ,  Myron A. Beigler ,  Emanuel Calenoff ,  Gerald L. Friesen ,  James L. Nichols

Inventor： Yuh-Geng Tsay ,  Myron A. Beigler ,  Emanuel Calenoff ,  Gerald L. Friesen ,  James L. Nichols

IPC: A61K39/35 ,  A61K39/00 ,  G01N33/53

CPC classification number: A61K39/35 ,  Y10S436/809

Abstract: A storage-stable, high potency allergenic extract is prepared by ultrafiltration, retaining fractions having molecular weights of from 1000 to 100,000, and treating the solution with gel polymer and/or carbon absorbents. The extract is dried to a moisture content of less than one weight percent water. The purified solution and aqueous reconstituted solutions of the dried extract provide a transparent, colorless solution which has greatly increased stability, remaining transparent and colorless for extended periods.

Abstract translation: 通过超滤制备储存稳定的高效力过敏原提取物，保留分子量为1000至100,000的级分，并用凝胶聚合物和/或碳吸收剂处理溶液。 将提取物干燥至含水量小于1重量％的水分。 干燥提取物的纯化溶液和水性重构溶液提供透明的无色溶液，其具有大大增加的稳定性，长时间保持透明和无色。

公开(公告)号：US20140134197A1

公开(公告)日：2014-05-15

申请号：US13423119

申请日：2012-03-16

Applicant: Emanuel Calenoff

Inventor： Emanuel Calenoff

IPC: C07K2/00 ,  G01N33/68

CPC classification number: G01N33/6896 ,  A61K38/00 ,  C07K7/06 ,  C07K14/4713 ,  G01N33/6854 ,  G01N2800/285

Abstract: The present invention provides peptides and methods for diagnosing and treating multiple sclerosis and wherein the method can also be applicable to the diagnosis and treatment of other immune disorders.

Abstract translation: 本发明提供了用于诊断和治疗多发性硬化症的肽和方法，并且其中该方法也可以应用于其他免疫疾病的诊断和治疗。

公开(公告)号：US6025477A

公开(公告)日：2000-02-15

申请号：US386221

申请日：1995-02-09

Applicant: Emanuel Calenoff

Inventor： Emanuel Calenoff

IPC: A61K38/00 ,  A61K41/00 ,  A61K47/48 ,  C07K14/47 ,  C07K14/78 ,  C07K16/18 ,  C07K16/46 ,  C12N5/18 ,  G01N33/533 ,  G01N33/543 ,  G01N33/544 ,  G01N33/564 ,  G01N33/68 ,  G01N33/92 ,  C07K17/00

CPC classification number: A61K47/48538 ,  A61K47/4843 ,  A61K47/48676 ,  C07K14/47 ,  C07K14/78 ,  C07K16/18 ,  C07K16/468 ,  G01N33/533 ,  G01N33/543 ,  G01N33/544 ,  G01N33/564 ,  G01N33/686 ,  G01N33/92 ,  A61K38/00 ,  G01N2800/323

Abstract: This invention provides purified antigens which are indicative of the presence of atherosclerotic plaque. Different concentrations of these antigens have been found to coincide with the progression of atherosclerosis. The subject invention also provides different hybridoma cell lines which produce monoclonal antibodies directed to antigens associated with atherosclerosis and a hybridoma cell line which produces monoclonal antibodies directed to antigen associated with normal artery and not with plaque. The atherosclerotic plaque antigen, and monoclonal antibodies made thereto, are used in various methods for detecting in a biological sample an antigen present in, and indicative of the presence of, atherosclerotic plaque. The monoclonal antibodies are also used in methods of imaging atherosclerotic plaque, and treating atherosclerosis. The methods of treating atherosclerosis include a method of digesting atherosclerotic plaque with enzymes, and a method of ablating atherosclerotic plaque using radiation. The subject invention also provides a method of treating atherosclerotic plaque by directly delivering a drug to the plaque. The subject invention further provides a method for treating atherosclerosis by blocking the synthesis of atherosclerotic plaque or by blocking binding of antibodies to the antigen.

Abstract translation: 本发明提供了指示存在动脉粥样硬化斑块的纯化抗原。 已经发现不同浓度的这些抗原与动脉粥样硬化的进展相一致。 本发明还提供了不同的杂交瘤细胞系，其产生针对与动脉粥样硬化相关的抗原的单克隆抗体和产生针对与正常动脉相关的抗原而不与斑块相关的抗原的单克隆抗体的杂交瘤细胞系。 动物动脉粥样硬化斑块抗原及其制备的单克隆抗体用于各种方法用于在生物样品中检测存在于动脉粥样硬化斑块中并存在动脉粥样硬化斑块的抗原。 单克隆抗体也用于成像动脉粥样硬化斑块和治疗动脉粥样硬化的方法。 治疗动脉粥样硬化的方法包括用酶消化动脉粥样硬化斑块的方法，以及使用辐射消融动脉粥样硬化斑块的方法。 本发明还提供了通过将药物直接递送至斑块来治疗动脉粥样硬化斑块的方法。 本发明还提供了通过阻断动脉粥样硬化斑块的合成或通过阻断抗体与抗原的结合来治疗动脉粥样硬化的方法。

公开(公告)号：US4849337A

公开(公告)日：1989-07-18

申请号：US144730

申请日：1988-01-14

Applicant: Emanuel Calenoff ,  Ruth M. Jones ,  Yuh-Geng Tsay ,  John R. Scott

Inventor： Emanuel Calenoff ,  Ruth M. Jones ,  Yuh-Geng Tsay ,  John R. Scott

IPC: G01N33/545 ,  G01N33/58 ,  G01N33/68

CPC classification number: G01N33/582 ,  G01N33/545 ,  G01N33/6854 ,  Y10S435/968 ,  Y10S436/809

Abstract: A method for identifying and quantifying allergen specific IgE levels in patent serum by conjugating the IgE in the serum with allergens adhering to an insoluble support, conjugating the serum IgE with an enzyme labeled anti-IgE antibody, contacting the enzyme label with a solution of a substrate which will yield a fluorescent product in the presence of the enzyme, and measuring the level of fluorescence in the solution. Special reagents and their manufacture are also disclosed.

Abstract translation: 通过将血清中的IgE与粘附在不溶性支持物上的过敏原缀合，将血清IgE与酶标记的抗IgE抗体缀合，使酶标记物接触到酶标记的溶液中来鉴定和定量专利血清中的变应原特异性IgE水平的方法 底物，其将在酶的存在下产生荧光产物，并测量溶液中的荧光水平。 还公开了特殊试剂及其制造。

公开(公告)号：US4528267A

公开(公告)日：1985-07-09

申请号：US476440

申请日：1983-03-17

Applicant: Emanuel Calenoff ,  Yuh-Geng Tsay ,  Ruth M. Jones ,  Scott, John R.

Inventor： Emanuel Calenoff ,  Yuh-Geng Tsay ,  Ruth M. Jones ,  Scott, John R.

IPC: G01N33/545 ,  G01N33/58 ,  G01N33/54

CPC classification number: G01N33/582 ,  G01N33/545 ,  Y10S436/809

Abstract: An inhibition assay for measuring the potency of allergen extracts by incubating a mixture of allergen extract and reference allergen specific IgE in a buffered solution with an insoluble support to which reference allergen is adhered. The conjugated IgE adhering to the insoluble support is reacted with an enzyme labeled anti-IgE antibody and the enzyme label is contacted with a solution of a substrate which will yield a fluorescent product in the presence of the enzyme. The level of fluoresence in the solution is measured. The percentage of inhibition of the allergen specific IgE is determined from fluorescence levels measured for various extract concentrations.

Abstract translation: 通过将缓冲溶液中的变应原提取物和参比变应原特异性IgE的混合物与参与变应原粘附的不溶性载体进行温育来测量变应原提取物的效力的抑制试验。 附着于不溶性载体的缀合的IgE与酶标记的抗IgE抗体反应，并且酶标记物与底物的溶液接触，所述底物将在酶的存在下产生荧光产物。 测量溶液中的荧光水平。 由各种提取物浓度测量的荧光水平确定变应原特异性IgE的抑制百分比。

公开(公告)号：US20080267988A1

公开(公告)日：2008-10-30

申请号：US12082515

申请日：2008-04-11

Applicant: Emanuel Calenoff

Inventor： Emanuel Calenoff

IPC: A61K39/00 ,  G01N33/53 ,  G01N33/567 ,  C07K16/42

CPC classification number: G01N33/564 ,  A61K38/00 ,  C07K7/06 ,  G01N2800/285

Abstract: Optimization and validation of a serum test confirms symptomatic autoimmune diseases e.g. multiple sclerosis (MS) or rheumatoid arthritis, and identifies early, silent diseases. The methods involve testing of subject sera for the presence of epitope-specific serum IgE and also non-IgE antibodies. The tests are immunoassays wherein serum autoantibodies complex with peptides structurally mimicking humoral, autoimmune epitopes on, for example, myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP) for MS. Each peptide: (1) is 5-6 amino acids long; (2) structurally and functionally mimics the surface region of its parent protein; and (3) offers a correct fit for the antigen binding site of a single specific autoantibody. Relapse prediction tests and therapies employ the peptides.

Abstract translation: 血清测试的优化和验证证实了症状性自身免疫疾病，例如 多发性硬化症（MS）或类风湿性关节炎，并确定早期，沉默性疾病。 该方法涉及测试受试血清中存在表位特异性血清IgE和非IgE抗体。 测试是免疫测定，其中血清自身抗体与肽结合模拟例如髓磷脂碱性蛋白（MBP），髓磷脂少突胶质细胞糖蛋白（MOG）和蛋白脂质蛋白（PLP））的体液，自身免疫表位。 每个肽：（1）长5-6个氨基酸; （2）在结构上和功能上模拟其亲本蛋白质的表面区域; 和（3）提供了单一特异性自身抗体的抗原结合位点的正确拟合。 复发预测测试和疗法使用肽。

公开(公告)号：US06892140B1

公开(公告)日：2005-05-10

申请号：US09723307

申请日：2000-11-27

Applicant: Emanuel Calenoff ,  Charles Ditlow

Inventor： Emanuel Calenoff ,  Charles Ditlow

IPC: A61K38/02 ,  C07K14/47 ,  C12P21/08 ,  G01N33/574 ,  G01N33/48 ,  A01N63/00 ,  A61K38/14 ,  A61K39/00 ,  A61K45/00

CPC classification number: C07K14/4748 ,  A61K38/02 ,  G01N33/57484 ,  G01N33/57492

Abstract: This invention relates to novel general methods and compositions that provide cancer-specific or highly cancer-associated antigens useful for diagnosis and treatment of cancer.

Abstract translation: 本发明涉及提供可用于诊断和治疗癌症的癌症特异性或高度癌症相关抗原的新的一般方法和组合物。

公开(公告)号：US5811248A

公开(公告)日：1998-09-22

申请号：US480434

申请日：1995-06-07

Applicant: Charles C. Ditlow ,  Francis W. Chen ,  Emanuel Calenoff

Inventor： Charles C. Ditlow ,  Francis W. Chen ,  Emanuel Calenoff

IPC: G01N33/533 ,  G01N33/92 ,  G01N33/574 ,  C07K16/18 ,  G01N33/53

CPC classification number: G01N33/92 ,  G01N33/533 ,  C07K2317/24 ,  G01N2800/323

Abstract: An antigen comprising 5,7 cholestadien-3.beta.-ol (7-dehydrocholesterol) or a compound having a structure similar to 5,7 cholestadien-3.beta.-ol and a quaternary ammonium salt is provided. Also provided is a method of generating an antibody using the aforementioned antigen, as well as antibodies produced thereby and fragments of such antibodies. The invention also provides a rat myeloma cell line Z2D3 73/30 1D10 and a murine-human chimeric monoclonal antibody produced thereby. A CDR-grafted antibody comprising a CDR region amino acid sequence from hybridoma Z2D3 or hybridoma Z2D3/3E5 and framework and constant region amino acid sequences from a human immunoglobulin is further provided. Also provided are methods for imaging atherosclerotic plaque, ablating atherosclerotic plaque, detecting and quantitatively determining in a sample an antigen indicative of the presence of atherosclerotic plaque, reducing the amount of atherosclerotic plaque in a blood vessel, and treating atherosclerosis in a subject. The invention also provides peptides having amino acid sequences which are the same or substantially the same as those of the aforementioned murine-human chimeric monoclonal antibody, as well as isolated nucleic acid sequences encoding therefore.

Abstract translation: 提供了包含5,7胆固醇-3β-醇（7-脱氢胆固醇）或具有类似于5,7胆固醇-3β-醇和季铵盐结构的化合物的抗原。 还提供了使用上述抗原产生抗体的方法，以及由此产生的抗体和这种抗体的片段。 本发明还提供了大鼠骨髓瘤细胞系Z2D3 73/30 1D10和由此产生的鼠 - 人嵌合单克隆抗体。 还提供了包含来自杂交瘤Z2D3或杂交瘤Z2D3 / 3E5的CDR区氨基酸序列和来自人免疫球蛋白的框架和恒定区氨基酸序列的CDR-移植抗体。 还提供了用于成像动脉粥样硬化斑块，消融动脉粥样硬化斑块的方法，在样品中检测和定量测定表明动脉粥样硬化斑块存在的抗原，减少血管中的动脉粥样硬化斑块的量，以及治疗受试者的动脉粥样硬化。 本发明还提供了具有与上述鼠 - 人嵌合单克隆抗体相同或基本相同的氨基酸序列的肽以及由此编码的分离的核酸序列。